Clinical trials: Anti-PD-1
Advanced Solid Tumor Cancer
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase…
- Trial name
- NCT04777994
- Testing
- ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Death-1 (PD-1) Inhibitor
- Where
- 30 sites in United States, France and 4 more
- Volunteers
- 248 people
- Sponsor
- Calico Life Sciences LLC
Nasopharyngeal Carcinoma (NPC)
Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
The main questions it aims to answer are: 1. Does the combination of GP induction chemotherapy and toripalimab improve the 3-year progression-free survival (PFS) compared to GP induction chemotherapy with placebo? 2.
- Trial name
- Navigation (NCT06712888)
- Testing
- TORIPALIMAB INJECTION (JS001 ) combine with GP chemotherapy
- Where
- 10 sites in China
- Volunteers
- 466 people
- Sponsor
- Sun Yat-sen University
Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic, and potential clinical benefit of PF-07209960…
- Conditions
- Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04628780
- Testing
- PF-07209960
- Where
- 13 sites in United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
Cervical Cancer
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
The primary objective of the study is to estimate the clinical benefit of cemiplimab + ISA101b after progression on first line chemotherapy, as assessed by objective response rate (ORR).
- Trial name
- NCT04646005
- Testing
- Cemiplimab, ISA101b
- Where
- 26 sites in United States, Belgium and 6 more
- Volunteers
- 113 people
- Sponsor
- Regeneron Pharmaceuticals
Locally Advanced Gastric Cancer
Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy
We plan to evaluate the efficacy and safety of proximal gastric vs. total gastric radical resection after SOX combined with anti-PD-1 neoadjuvant therapy in locally advanced upper gastric cancer
- Trial name
- TJHGC01 (NCT06597227)
- Testing
- Proximal radical gastrectomy, Total radical gastrectomy
- Where
- China
- Volunteers
- 404 people
- Sponsor
- Guihua Wang
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
The prognosis for patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who refuse or are ineligible for transplant is poor.
- Trial name
- NCT06393361
- Testing
- Chidamide; Decitabine; Anti-PD-1 Antibody, Brentuximab Vedotin, anti-PD-1 antibody.
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
SCLC, Extensive Stage
A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC
Evaluate Clinical Efficacy, Safety and Pharmacokinetics of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination with Chemotherapy (Carboplatin-Etoposide) in Previously Untreated Japanese Patients…
- Trial name
- NCT06812260
- Testing
- HLX10+chemo
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Shanghai Henlius Biotech
Thyroid Cancer
Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer
To determine the efficacy and safety of anti-PD-1 antibody Camrelizumab combined with Apatinib for neoadjuvant therapy in locally advanced thyroid cancer.
- Trial name
- NCT04612894
- Testing
- Camrelizumab and Apatinib, surgery, core needle biopsy
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Fudan University
Advanced Solid Tumor
Study of AGEN1571 in Participants With Advanced Solid Tumors
This is an open-label, Phase 1, 2-part trial to determine recommended phase 2 doses (RP2Ds) and evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of AGEN1571 both as a monotherapy and in combination…
- Trial name
- NCT05377528
- Testing
- AGEN1571, Balstilimab, Botensilimab
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Agenus Inc.
Nasopharyngeal Carcinoma
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma
This is a multicenter, single-arm open-label, phase II study to evaluate the anti-tumor activity, safety, PK and immunogenicity of AK105 (Anti-PD1 antibody) in patients with metastatic nasopharyngeal carcinoma who have progressed…
- Trial name
- NCT03866967
- Testing
- AK105
- Where
- 2 sites in China
- Volunteers
- 130 people
- Sponsor
- Akeso
IO Resistant Squamous and Nonsquamous NSCLC
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
Lung cancer is one of the most common forms of cancer. One common type is non-small cell lung cancer (NSCLC). NSCLC happens when abnormal cells in the lungs grow too fast. This can stop the lungs from working normally.
- Trial name
- MarsLight-11 (NCT07217301)
- Testing
- TAK-928, Control Arm
- Where
- 50 sites in United States, China and 1 more
- Volunteers
- 1,200 people
- Sponsor
- Takeda
Advanced Unresectable Solid Tumor, Metastatic Solid Tumor
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the…
- Trial name
- NCT04137900
- Testing
- TAB004, Toripalimab
- Where
- 24 sites in United States
- Volunteers
- 499 people
- Sponsor
- TopAlliance Biosciences
Melanoma, Immune-related Adverse Event
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma
Primary Objective: To evaluate the effectiveness of Thymosin Alpha-1 combined with PD-1 monoclonal antibody in elderly patients with advanced melanoma .
- Conditions
- Melanoma, Immune-related Adverse Event, Immune Checkpoint Inhibitor
- Trial name
- NCT07644897
- Testing
- Thymosin Alpha 1 and Anti-PD-1 monoclonal antibody
- Where
- 2 sites in China
- Volunteers
- 55 people
- Sponsor
- Sun Yat-sen University
Tumor, Solid
BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors
BDB001-201 is a multi-center, open-label, Phase II clinical trial to evaluate the efficacy and safety of BDB001 in the treatment of subjects with advanced solid tumors that have progressed on anti-PD-1 or anti-PD-L1 mAb treatment.
- Trial name
- NCT04819373
- Testing
- BDB001
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Eikon Therapeutics
Advanced Solid Tumors, Metastatic Solid Tumors
NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies
This study is a multicenter, open-label, proof-of-concept study aiming to assess the clinical and biological impact of NP137 when added to standard PD-1/PD-L1 blockade therapy in 3 independent cohorts of advanced or metastatic…
- Trial name
- IMMUNONET (NCT05605496)
- Testing
- NP137, anti-PD-1/PD-L1
- Where
- 5 sites in France
- Volunteers
- 57 people
- Sponsor
- Centre Leon Berard
Carcinoma, Non-Small-Cell Lung
Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The objective of this trial is to study REGN4659 and cemiplimab in treatment-experienced, non-small cell lung cancer (NSCLC) patients. There are 2 phases of this study: a dose escalation phase and a dose expansion phase.
- Trial name
- NCT03580694
- Testing
- REGN4659, Cemiplimab
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Regeneron Pharmaceuticals
Ovarian Neoplasms, Recurrent Ovarian Carcinoma
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and VEGF bispecific antibody (AK112) combined with PARP inhibitor in patients with recurrent ovarian cancer.
- Conditions
- Ovarian Neoplasms, Recurrent Ovarian Carcinoma, Relapsed Ovarian Cancer, Ovarian Cancer
- Trial name
- NCT04999605
- Testing
- AK112 low dose, AK112 medium dose, AK112 high dose
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Akeso
Breast Cancer
Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer
This is a multi-center, prospective, interventional, single-arm clinical trial. In the study, patients with her2-positive recurrent or metastatic breast cancer who were initially treated were included.
- Trial name
- NCT05291910
- Testing
- Inetetamab, Toripalimab, Albumin-Bound Paclitaxel
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Chinese Academy of Medical Sciences
Hepatocellular Carcinoma (HCC), Downstaging
Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC Downstaging
The goal of this observational study is to learn about the long-term treatment outcomes for patients with initially unresectable hepatocellular carcinoma (HCC) who achieve successful downstaging with the combination therapy of…
- Conditions
- Hepatocellular Carcinoma (HCC), Downstaging, Liver Resection, Lenvatinib
- Trial name
- NCT07581769
- Testing
- Liver resection, TACE plus Lenvatinib and PD1 inhibiter
- Where
- 2 sites in China
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Advanced Melanoma
A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)
Abbreviated Title: An explorative Phase II study of Anti-PD-1 (Pembrolizumab) in patients with advanced melanoma (ADAPTeM) Trial Phase: Phase II Clinical Indication: Stage III unresectable/stage IV metastatic melanoma Trial Type…
- Trial name
- ADAPTeM (NCT02663258)
- Testing
- Pembrolizumab
- Sponsor
- Royal Marsden NHS Foundation Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.